Oral Ibezapolstat ACX-362E for Treating Recurrent Clostridioides Difficile Infection in Adults With Multiple Recurrences
Led by Acurx Pharmaceuticals Inc. · Updated on 2026-10-16
20
Participants Needed
19
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of ibezapolstat, an oral drug, for treating recurrent Clostridioides difficile infection CDI in adults who have had three or more CDI episodes in the past year. This phase 2, open-label, single-arm study focuses on adults aged 18 to 90 years who have experienced multiple recurrent infections. The trial aims to assess how well ibezapolstat treats the infection and reduces the chances of it coming back.
Participants will receive ibezapolstat 450 mg by mouth every 12 hours with food for 14 days, totaling 28 doses. After treatment, participants will be monitored through several follow-up periods including Day 16 for Clinical Cure, Day 42 for Sustained Clinical Cure, and up to Week 24 to observe recurrence rates and Extended Clinical Cure. The treatment and follow-up schedule is designed to evaluate the drugs effect over time on CDI recurrence and recovery.
During the study, participants will undergo assessments for diarrhea resolution, stool tests for infection, and monitoring of their fecal microbiome changes from Day 1 through Week 24. Researchers will track safety, tolerability, and treatment response through clinical visits and laboratory evaluations. The total participation duration includes treatment and follow-up assessments up to approximately 24 weeks to fully understand the drugs impact on recurrent CDI.
CONDITIONS
Brief Title
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Research Team
D
Dee Rodriguez
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Ibezapolstat (investigational)
Standard‑of‑care antibiotics (vancomycin or fidaxomicin)
What it is
An investigational oral antibiotic targeting DNA polymerase IIIC, given as 450 mg every 12 hours for 14 days in adults with recurrent C. difficile infection.
Current standard-of-care antibiotics for recurrent CDI include oral vancomycin or fidaxomicin regimens as recommended by recent clinical guidelines.
Role in trial
Study intervention evaluated in a single‑group trial for patients with multiple CDI recurrences.
Not studied within this trial but represents comparator therapy patients would receive in current medical practice.
Primary use
To treat recurrent C. difficile infection and reduce recurrence.
To treat recurrent CDI and prevent further episodes, as standard therapy.
How it is administered
Given orally as 450 mg capsules twice daily for 14 days.
Given orally following guideline‑recommended dosing regimens (eg, fidaxomicin 200 mg twice daily for 10 days or tapered/pulsed vancomycin for recurrence).
Evidence for efficacy or outcomes
Phase 2a data show favorable clinical cure rates and microbiome‑preserving properties; larger trials pending.
Supported by clinical experience and guidelines favoring fidaxomicin or tapered vancomycin for recurrent CDI.
Important risks
Safety profile assessed in early‑phase studies but full adverse effects unknown.
Generally well‑known adverse effects; fidaxomicin linked with lower recurrence, vancomycin associated with microbiome disruption.
Important limitations
Single‑group design without randomized control group; small sample and early‑phase data.
May not prevent recurrence in all patients; microbiota disruption especially with vancomycin may predispose to relapse.
Patient impact
Potential for reduced recurrence and microbiome‑friendly therapy pending further trials.
Accepted treatments that reduce CDI recurrence in many patients, though relapse may still occur.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 90Years
All Genders
Eligibility Criteria
You may qualify if you...
Confirmed diagnosis of CDI with diarrhea of at least 3 unformed stools within 24 hours and positive stool test for C. difficile toxins
Three or more CDI episodes in the past 12 months, including the current episode
At least one prior CDI episode treated with oral vancomycin or fidaxomicin
You will not qualify if you...
Severe or life-threatening CDI with low blood pressure, septic shock, peritoneal signs, ileus, or toxic megacolon
More than 24 hours of antibiotics given for the current CDI episode prior to study
Received a live biotherapeutic product (Rebyota or Vowst) in the past 12 weeks
Received or currently using anti-C. difficile antibodies such as IVIG or bezlotoxumab
Active inflammatory bowel disease with chronic diarrhea in the past 12 weeks or without mucosal healing within the past year
Active irritable bowel syndrome with chronic diarrhea in the past 12 weeks
Active gastroenteritis caused by certain bacteria, parasites, or viruses within the past 2 weeks
Major gastrointestinal surgery within 3 months before enrollment
Severely compromised immune system
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 14 days
Participants take ibezapolstat 450 mg by mouth every 12 hours with food for 14 days.
Daily dosing with scheduled clinical visits
Follow-up
Duration - Up to 24 weeks
Participants are monitored for clinical cure, sustained cure, and recurrence of infection up to 24 weeks after treatment.
Scheduled visits at Days 16, 42, 70, and Weeks 8, 12, and 24
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Oral Ibezapolstat ACX-362E for Treating Recurrent Clostridioides Difficile Infection in Adults With Multiple Recurrences
Fecal Microbiota Transplantation by Colonoscopy to Treat Recurrent Clostridium Difficile Infection
Long-Term Real-World Study on the Safety and Effectiveness of Fecal Microbiota Transplantation for Various Diseases
Randomized Placebo-Controlled Study of VE303 Capsules to Prevent Recurrence of Clostridioides Difficile Infection
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study.
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).
L Clifford McDonald, Dale N Gerding, Stuart Johnson...
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial.